Acasti Pharma Price Target & Analyst Ratings (NASDAQ:ACST)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

5 Wall Street analysts have issued ratings and price targets for Acasti Pharma in the last 12 months. Their average twelve-month price target is $6.94, suggesting that the stock has a possible upside of 252.16%. The high price target for ACST is $7.75 and the low price target for ACST is $6.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."

Acasti Pharma (NASDAQ:ACST) Consensus Price Target History

Acasti Pharma (NASDAQ:ACST) Analyst Ratings History

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
8/29/2019	B. Riley	Initiated Coverage	Buy	$7.75	High
8/15/2019	HC Wainwright	Reiterated Rating	Buy		High
7/18/2019	CIBC	Initiated Coverage	Outperform ➝ Outperform	$7.00	High
7/18/2019	Oppenheimer	Initiated Coverage	Outperform	$7.00 ➝ $7.00	High
7/9/2019	Aegis	Initiated Coverage	Buy		Medium
1/29/2018	Dawson James	Reiterated Rating	Buy		Low
1/5/2018	Benchmark	Initiated Coverage	Buy	$7.00	High

(Data available from 10/21/2017 forward)